BCI
MDGL icon

Brinker Capital Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Brinker Capital Investments’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$523 Buy
+1
New +$478 ﹤0.01% 1942

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brinker Capital Investments's MDGL Position: Q1 2026 in Review

Brinker Capital Investments reduced its Madrigal Pharmaceuticals (MDGL) stake by 34% in Q1 2026, selling an estimated $866K and leaving 3,537 shares worth $1.85M. The position accounts for 0.02% of the portfolio, ranked #790.

Brinker Capital Investments first reported a position in MDGL in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.12M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Brinker Capital Investments held 3,537 shares of Madrigal Pharmaceuticals worth $1.85M as of Q1 2026.
  • Brinker Capital Investments sold 1,813 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $866K.
  • Madrigal Pharmaceuticals made up 0.02% of Brinker Capital Investments's portfolio in Q1 2026, its #790 holding.
  • Brinker Capital Investments first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Brinker Capital Investments's Madrigal Pharmaceuticals position peaked at $3.12M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.